Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA.
Kastritis E, et al.
Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21.
Am J Hematol. 2023.
PMID: 37340832
Clinical Trial.
No abstract available.